Literature DB >> 6497355

Hereditary dysphasic dementia and the Pick-Alzheimer spectrum.

J C Morris, M Cole, B Q Banker, D Wright.   

Abstract

Hereditary dysphasic dementia is described in terms of its clinicopathological, ultrastructural, and transmissibility characteristics. Its mode of inheritance is autosomal dominant, and its clinical manifestations of progressive dementia and severe dysphasic disturbances are expressed in late adulthood. Complete neuropathological examination of four patients reveals findings typical for Pick's disease (asymmetrical focal cerebral atrophy), Alzheimer's disease (profuse neuritic plaques), and paralysis agitans (neuronal depigmentation, depletion, and Lewy body formation in substantia nigra) in addition to a striking but nonspecific spongiform degeneration of superficial cortical layers. This unique combination of gross morphological and histopathological features qualifies hereditary dysphasic dementia as a distinct entity, but its precise relationship to the well-recognized adult cortical dementias has been difficult to establish by conventional classification methods. This disorder and other unusual dementing illnesses may be best considered as part of a Pick-Alzheimer spectrum of cortical neuronal degenerations.

Entities:  

Mesh:

Year:  1984        PMID: 6497355     DOI: 10.1002/ana.410160407

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

1.  Frontotemporal dementia classification and neuropsychiatry.

Authors:  Tiffany W Chow; Bruce L Miller; Kyle Boone; Fred Mishkin; Jeffrey L Cummings
Journal:  Neurologist       Date:  2002-07       Impact factor: 1.398

2.  Pick body-like inclusions in the dentate fascia of the hippocampus in Alzheimer's disease.

Authors:  D W Dickson; S H Yen; D S Horoupian
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

3.  Progressive aphasia with right-sided extrapyramidal signs: another manifestation of localised cerebral atrophy.

Authors:  P J Goulding; B Northen; J S Snowden; N Macdermott; D Neary
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

4.  Severe aggravation of blepharospasm in Fisher's syndrome.

Authors:  E Garcia-Albea
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

Review 5.  The non-fluent/agrammatic variant of primary progressive aphasia.

Authors:  Murray Grossman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

Review 6.  Diagnostic confirmation, severity, and subtypes of Alzheimer's disease. A short review on clinico-pathological correlations.

Authors:  H Förstl; P Fischer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

7.  HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin.

Authors:  Odity Mukherjee; Pau Pastor; Nigel J Cairns; Sumi Chakraverty; John S K Kauwe; Shantia Shears; Maria I Behrens; John Budde; Anthony L Hinrichs; Joanne Norton; Denise Levitch; Lisa Taylor-Reinwald; Michael Gitcho; P-H Tu; Lea Tenenholz Grinberg; Rajka M Liscic; Javier Armendariz; John C Morris; Alison M Goate
Journal:  Ann Neurol       Date:  2006-09       Impact factor: 10.422

8.  Familial dementia with Lewy bodies with an atypical clinical presentation.

Authors:  Lauren T Bonner; Debby W Tsuang; Monique M Cherrier; Charisma J Eugenio; Q Du Jennifer; Ellen J Steinbart; Pornprot Limprasert; Albert R La Spada; Benjamin Seltzer; Thomas D Bird; James B Leverenz
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-03       Impact factor: 2.680

9.  Dementia presenting with aphasia: clinical characteristics.

Authors:  M F Mendez; B A Zander
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-06       Impact factor: 10.154

Review 10.  ALS and FTLD: two faces of TDP-43 proteinopathy.

Authors:  R M Liscic; L T Grinberg; J Zidar; M A Gitcho; N J Cairns
Journal:  Eur J Neurol       Date:  2008-08       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.